"""
Question: 1101 

Evidence: This was a multicentre retrospective cohort study conducted in nine tertiary hospitals in Spain. At the time of the analysis, 81 (96.4%) patients had achieved 48 weeks of follow-up and 71 (87.7%; 95% CI 78.7%–93.2%) of them showed VL <50 copies/mL.

Rationale: The paper presents new clinical outcomes from a defined cohort with 48-week follow-up; these data and analyses have not been previously published within the paper, indicating the study reports previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Cumulative historic genotyping tests were evaluated and resistance-associated mutations (RAMs) detected by Sanger population sequencing were considered as defined by the IAS-USA guidelines. Historical genotypes were available in 50 (59.5%) patients and showed 44 (88%) patients with NRTI RAMs, 21 (42%) with NNRTI RAMs, 12 (24%) with primary PI RAMs and 7 (14%) with integrase strand transfer inhibitor (INSTI) RAMs.

Rationale: The study references and summarizes results of previously performed clinical genotyping (RAMs) but does not present nucleotide or amino acid sequence data or new sequencing results in the paper.

Answer: No
"""

"""
Question: 1103 

Evidence: This was a multicentre retrospective cohort study conducted in nine tertiary hospitals in Spain. The study records clinical, laboratory, and historical genotyping data; no laboratory in vitro experiments are described.

Rationale: The methods and results focus on clinical outcomes and historical genotyping; there is no description of in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: Cumulative historic genotyping tests were evaluated and resistance-associated mutations (RAMs) detected by Sanger population sequencing were considered as defined by the IAS-USA guidelines. The paper does not describe any phenotypic susceptibility assays or in vitro IC measurements.

Rationale: Only genotypic (RAM) information is discussed; no novel in vitro antiretroviral susceptibility data (e.g., IC50/IC90 or fold change) are reported.

Answer: No
"""

"""
Question: 2101 

Evidence: Cumulative historic genotyping tests were evaluated and resistance-associated mutations (RAMs) detected by Sanger population sequencing were considered as defined by the IAS-USA guidelines. The paper does not provide any sequence repository identifiers or accession numbers.

Rationale: Although historical genotypes were reviewed, the manuscript does not report GenBank accession numbers.

Answer: No
"""

"""
Question: 2102 

Evidence: Historical genotypes were available in 50 (59.5%) patients. No GenBank accession numbers for any sequenced isolates are provided in the text.

Rationale: The paper does not list accession numbers for any patient-derived sequences.

Answer: No
"""

"""
Question: 2103 

Evidence: The manuscript reports results from historical genotyping but does not include sequence identifiers. No GenBank accession numbers appear anywhere in the provided text.

Rationale: Since no accession numbers are reported, there are none to list.

Answer: NA
"""

"""
Question: 2202 

Evidence: Historical genotypes were available in 50 (59.5%) patients and showed 44 (88%) patients with NRTI RAMs, 21 (42%) with NNRTI RAMs, 12 (24%) with primary PI RAMs and 7 (14%) with INSTI RAMs. There were five (10%) patients that had some level of resistance to rilpivirine (Table 2).

Rationale: The paper includes Table 2 listing, by patient, specific mutations (e.g., K103N, M184V, K65R), which constitutes per-individual mutation lists derived from sequencing.

Answer: Yes
"""

"""
Question: 2301 

Evidence: Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection. The combination of boosted darunavir plus rilpivirine has shown good effectiveness and tolerability in this cohort.

Rationale: The title explicitly states HIV-1 infection; the study population consisted of HIV-1–infected individuals.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: The study describes a clinical cohort and summarizes genotypic resistance classes. No subtype information (e.g., subtype B, C) is reported in the text.

Rationale: The paper does not mention HIV-1 subtypes for any sequenced viruses.

Answer: NA
"""

"""
Question: 2303 

Evidence: Cumulative historic genotyping tests were evaluated and resistance-associated mutations (RAMs) detected by Sanger population sequencing were considered as defined by the IAS-USA guidelines. Historical genotypes were available in 50 (59.5%) patients and showed NRTI, NNRTI, PI, and INSTI RAMs.

Rationale: The presence of NRTI, NNRTI, PI, and INSTI RAMs implies sequencing of reverse transcriptase, protease, and integrase regions (pol). Although not explicitly named, these are the genes assessed by the genotyping.

Answer: Protease, reverse transcriptase, integrase
"""

"""
Question: 2304 

Evidence: Cumulative historic genotyping tests were evaluated and resistance-associated mutations (RAMs) detected by Sanger population sequencing were considered as defined by the IAS-USA guidelines. Historical genotypes were available in 50 (59.5%) patients and showed NRTI, NNRTI, PI and INSTI RAMs.

Rationale: Reporting RAMs from protease, reverse transcriptase, and integrase indicates results derived from HIV pol gene sequencing.

Answer: Yes
"""

"""
Question: 2401 

Evidence: This was a multicentre retrospective cohort study conducted in nine tertiary hospitals in Spain. All adult HIV-infected patients who started a once-daily treatment with darunavir … plus rilpivirine … were included.

Rationale: The cohort and any genotypes reported are from patients treated in Spain.

Answer: Spain
"""

"""
Question: 2402 

Evidence: All adult HIV-infected patients who started a once-daily treatment … from January 2015 to January 2019 were included. Patients were followed up for 48 weeks … until data analysis in June 2019.

Rationale: The paper specifies years of treatment initiation and follow-up, but not the years when sequencing samples were obtained for the historical genotypes.

Answer: NA
"""

"""
Question: 2502 

Evidence: Cumulative historic genotyping tests were evaluated and resistance-associated mutations (RAMs) detected by Sanger population sequencing were considered as defined by the IAS-USA guidelines. Historical genotypes were available in 50 (59.5%) patients.

Rationale: The paper explicitly states that RAMs came from Sanger population sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Cumulative historic genotyping tests were evaluated and resistance-associated mutations (RAMs) detected by Sanger population sequencing were considered. No next-generation sequencing methods are described.

Rationale: Only Sanger population sequencing is mentioned; NGS is not reported.

Answer: No
"""

"""
Question: 2504 

Evidence: Cumulative historic genotyping tests were evaluated … detected by Sanger population sequencing. The paper does not describe cloning of samples prior to sequencing.

Rationale: No mention of cloning in the methods; standard population Sanger genotyping does not involve cloning.

Answer: NA
"""

"""
Question: 2505 

Evidence: Cumulative historic genotyping tests were evaluated … detected by Sanger population sequencing. There is no mention of single genome sequencing.

Rationale: The sequencing approach described is population Sanger, not single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: The study reports only clinical outcomes and historical genotypes. No molecular cloning procedures are described.

Rationale: There is no mention of molecular cloning in the methods or results.

Answer: No
"""

"""
Question: 2601 

Evidence: Cumulative historic genotyping tests were evaluated … detected by Sanger population sequencing. The source material for genotyping (e.g., plasma vs PBMC) is not specified.

Rationale: The paper does not state whether genotyping was performed on plasma HIV RNA.

Answer: NA
"""

"""
Question: 2602 

Evidence: Cumulative historic genotyping tests were evaluated … detected by Sanger population sequencing. The manuscript does not specify PBMC-based sequencing.

Rationale: There is no information indicating PBMC HIV sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: Historical genotypes were available in 50 (59.5%) patients. The sample type for those genotypes (plasma vs PBMC) is not provided.

Rationale: Without sample-type details, the number of plasma-sequenced samples cannot be determined.

Answer: NA
"""

"""
Question: 2604 

Evidence: Historical genotypes were available in 50 (59.5%) patients. The paper does not specify whether any genotyping was performed from PBMCs.

Rationale: No counts of PBMC sequencing are provided.

Answer: NA
"""

"""
Question: 2605 

Evidence: Fifty-nine (70.2%) patients had VL <50 copies/mL at their inclusion in the study. Historical genotypes were available in 50 (59.5%) patients, but the timing and viremia status at sampling are not described.

Rationale: The paper does not specify whether the sequenced samples (historical genotypes) were obtained during active replication.

Answer: NA
"""

"""
Question: 2606 

Evidence: Cumulative historic genotyping tests were evaluated … detected by Sanger population sequencing. The paper does not indicate sequencing from proviral DNA.

Rationale: There is no evidence that sequencing was performed on proviral DNA reservoirs.

Answer: No
"""

"""
Question: 2701 

Evidence: All adult HIV-infected patients who started a once-daily treatment with darunavir … plus rilpivirine … were included. 

Rationale: The study explicitly includes only adult patients; therefore, no infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: This was a multicentre retrospective cohort study conducted in nine tertiary hospitals in Spain. Patients were followed up for 48 weeks, until VF or treatment change … or until data analysis.

Rationale: This is an observational cohort, not a clinical trial; participants were not in a trial as part of this study.

Answer: No
"""

"""
Question: 2703 

Evidence: This was a multicentre retrospective cohort study conducted in nine tertiary hospitals in Spain. 

Rationale: Because it is not a clinical trial, it is not the case that all individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: Historical genotypes were available in 50 (59.5%) patients. Cumulative historic genotyping tests were evaluated.

Rationale: The number of individuals with sequencing data (historical genotypes) is explicitly given as 50.

Answer: 50
"""

"""
Question: 3102 

Evidence: Historical genotypes were available in 50 (59.5%) patients. A total of 84 patients were included.

Rationale: Only 50 of 84 had historical genotypes, so not all underwent HIV sequencing.

Answer: No
"""

"""
Question: 4101 

Evidence: Number of previous ART combinations, median (IQR) 6 (4–9). Prior NRTI failure, yes, n (%) 61 (72.6).

Rationale: The cohort is heavily ART-experienced; there is no indication of ART-naive individuals with sequences reported.

Answer: No
"""

"""
Question: 4102 

Evidence: Historical genotypes were available in 50 (59.5%) patients and showed RAMs. Number of previous ART combinations, median (IQR) 6 (4–9).

Rationale: The sequencing information (historical genotypes) is from ART-experienced individuals.

Answer: Yes
"""

"""
Question: 4103 

Evidence: The cohort had a median of six prior regimens and high rates of prior class failures. There is no mention of ART-naive individuals being sequenced.

Rationale: Sequences are only from ART-experienced persons; none from ART-naive.

Answer: No
"""

"""
Question: 4104 

Evidence: The study population is ART-experienced with multiple prior regimens. No ART-naive sequencing is described.

Rationale: As there are no ART-naive individuals with sequences reported, the number is zero.

Answer: 0
"""

"""
Question: 4105 

Evidence: Number of previous ART combinations, median (IQR) 6 (4–9). The paper summarizes classes and prior failures but does not provide per-individual complete ART histories.

Rationale: Only aggregate/summary ART histories are provided, not complete histories for each individual.

Answer: No
"""

"""
Question: 4201 

Evidence: The study is a switch/rescue cohort of ART-experienced patients. No data on newly infected, untreated individuals are presented.

Rationale: Transmitted drug resistance prevalence pertains to newly infected or untreated populations, which is not addressed here.

Answer: No
"""

"""
Question: 4202 

Evidence: The cohort consists of ART-experienced patients with historical genotypes. There is no analysis of pretreatment resistance in treatment-naive individuals.

Rationale: Pretreatment resistance prevalence is not reported.

Answer: No
"""

"""
Question: 4301 

Evidence: Current ART regimen, n (%): 2 NRTIs + INSTI; 2 NRTIs + PI; 2 NRTIs + NNRTI; PI-based dual therapy; PI-based monotherapy; 3-family regimen. Prior NRTI failure, NNRTI failure, and PI failure are also reported.

Rationale: Individuals received regimens including NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTIs, NNRTIs, PIs, INSTIs
"""

"""
Question: 4302 

Evidence: Current ART regimen, n (%): 2 NRTIs + INSTI 13 (15.5). Historical genotypes showed 7 (14%) with INSTI RAMs.

Rationale: The paper reports individuals who received integrase inhibitors.

Answer: Yes
"""

"""
Question: 4303 

Evidence: Current ART regimen included 2 NRTIs + PI, PI-based dual therapy, and PI-based monotherapy. Furthermore, darunavir, boosted with either cobicistat or ritonavir, is the preferred PI … and was the core of the study regimen.

Rationale: The study includes extensive PI use, including darunavir.

Answer: Yes
"""

"""
Question: 4304 

Evidence: All adult HIV-infected patients who started a once-daily treatment with darunavir 800 mg boosted with either ritonavir or cobicistat plus rilpivirine 25 mg were included. A total of 84 patients were included.

Rationale: All participants received the same study ART (boosted darunavir plus rilpivirine).

Answer: Yes
"""

"""
Question: 4305 

Evidence: Historical genotypes were available in 50 patients and showed 7 (14%) with INSTI RAMs. Current ART regimen included 2 NRTIs + INSTI in 13 (15.5%).

Rationale: Because some had prior INSTI exposure and RAMs, not all were INSTI-naive.

Answer: No
"""

"""
Question: 4403 

Evidence: Number of previous ART combinations, median (IQR) 6 (4–9). 

Rationale: The paper does not provide the exact count of individuals with more than one prior regimen, only summary statistics.

Answer: NA
"""

"""
Question: 4404 

Evidence: Number of previous ART combinations, median (IQR) 6 (4–9). 

Rationale: The exact number with more than two prior regimens is not reported, only the distribution summary.

Answer: NA
"""

"""
Question: 4405 

Evidence: Number of previous ART combinations, median (IQR) 6 (4–9). 

Rationale: The IQR indicates variability in number of regimens, so not all received the same number.

Answer: No
"""

"""
Question: 4406 

Evidence: Number of previous ART combinations, median (IQR) 6 (4–9). 

Rationale: With a median of six prior combinations, it is clear not all individuals received only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: Current ART regimens before switch included 2 NRTIs + INSTI in 13 (15.5%) but specific INSTIs are not named. The paper discusses dolutegravir in the introduction/discussion as context but not as a drug received by this cohort.

Rationale: The manuscript does not report how many individuals received dolutegravir.

Answer: NA
"""

"""
Question: 4502 

Evidence: All adult HIV-infected patients who started a once-daily treatment with darunavir 800 mg boosted with either ritonavir 100 mg or cobicistat 150 mg plus rilpivirine 25 mg from January 2015 to January 2019 were included. A total of 84 patients were included.

Rationale: Every included participant initiated boosted darunavir; thus 84 individuals received darunavir.

Answer: 84
"""

"""
Question: 5101 

Evidence: Historical genotypes were available in 50 (59.5%) patients and showed 44 (88%) patients with NRTI RAMs, 21 (42%) with NNRTI RAMs, 12 (24%) with primary PI RAMs and 7 (14%) with INSTI RAMs. There were 25 (50%) and 6 (12%) patients with documented RAMs against two and three ARV classes, respectively.

Rationale: Although counts per class are provided, the exact number of individuals with at least one RAM (across any class) is not explicitly given beyond “≥44”; therefore the precise number cannot be determined.

Answer: NA
"""

"""
Question: 5102 

Evidence: Historical genotypes were available in 50 (59.5%) patients and showed … 7 (14%) with integrase strand transfer inhibitor (INSTI) RAMs. 

Rationale: The paper directly reports the count of individuals with INSTI RAMs.

Answer: 7
"""

"""
Question: 5103 

Evidence: Historical genotypes were summarized by drug class (NRTI, NNRTI, PI, INSTI). Specific TDF-resistance mutations or counts are not provided beyond occasional examples in Table 2.

Rationale: The number with TDF-associated resistance (e.g., K65R) is not quantified in the cohort.

Answer: NA
"""

"""
Question: 5104 

Evidence: Regarding VF, resistance testing was performed in three out of four patients and none of them showed new RAMs. Only one of them had NNRTI RAMs at baseline (an isolated K103N mutation that was not seen at VF).

Rationale: No INSTI-resistance mutations emerged during the study; thus none “developed” in individuals.

Answer: None
"""

"""
Question: 6101 

Evidence: Cumulative historic genotyping tests were evaluated … detected by Sanger population sequencing. The methods and results do not include any phenotypic susceptibility testing.

Rationale: The study reports only genotypic resistance; no phenotypic assay method is described.

Answer: NA
"""

"""
Question: 6102 

Evidence: The paper does not describe any in vitro susceptibility assays or IC measurements. Results focus on viral load outcomes and genotypic RAMs.

Rationale: No novel IC50/IC90 data are reported.

Answer: No
"""

"""
Question: 6103 

Evidence: There are no phenotypic susceptibility results or fold-change analyses presented. The study evaluates clinical effectiveness and genotypic resistance only.

Rationale: Without phenotypic assays, there are no IC50 fold change values.

Answer: No
"""

"""
Question: 6104 

Evidence: No phenotypic susceptibility testing methods or assays are described in Patients and methods. The study relies on historical genotyping and clinical outcomes.

Rationale: Since no phenotypic testing was performed, no assay type can be specified.

Answer: NA
"""

"""
Question: 6105 

Evidence: The study reports clinical virologic outcomes and laboratory safety parameters. Replication capacity measurements are not mentioned.

Rationale: No replication capacity data are reported.

Answer: No
"""

"""
Question: 6106 

Evidence: The paper does not report any phenotypic susceptibility testing. It focuses on a clinical switch regimen and genotypic RAM summaries.

Rationale: Without phenotypic testing, no drugs were tested for phenotypic susceptibility in this study.

Answer: NA
"""

"""
Question: 7101 

Evidence: This was a multicentre retrospective cohort study conducted in nine tertiary hospitals in Spain. The paper reports only clinical outcomes and genotypic resistance summaries; no laboratory-engineered site-directed mutants are described.

Rationale: No site-directed mutagenesis experiments or engineered isolates are present.

Answer: No
"""

"""
Question: 7102 

Evidence: The study is entirely clinical and observational, with no in vitro passage experiments described. Resistance testing referenced is clinical genotyping.

Rationale: There are no in vitro passage-derived isolates reported.

Answer: No
"""